DR. MARTENS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 79.25 GBX | +1.08% |
|
-2.04% | -10.55% |
| Apr. 29 | Deutsche Bank Initiates Dr. Martens at Hold | MT |
| Apr. 29 | Deutsche Bank likes Frasers; Barclays cuts JD | AN |
Valuation
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 4,532 | 2,388 | 1,424 | 762.3 | - | - |
| Enterprise Value (EV) 1 | 4,706 | 2,554 | 1,712 | 1,112 | 1,113 | 1,107 |
| P/E ratio | 126 x | 13.2 x | 11 x | 11.2 x | 25.5 x | 14.8 x |
| Yield | - | 2.3% | 4.1% | 7.36% | 4.13% | 4.62% |
| Capitalization / Revenue | 5.86 x | 2.63 x | 1.42 x | 0.86 x | 0.9 x | 0.85 x |
| EV / Revenue | 6.09 x | 2.81 x | 1.71 x | 1.25 x | 1.31 x | 1.23 x |
| EV / EBITDA | 21 x | 9.71 x | 6.99 x | 5.7 x | 7.72 x | 5.96 x |
| EV / FCF | 27.7 x | 19.3 x | 66.1 x | 19.7 x | 16.3 x | 22.6 x |
| FCF Yield | 3.61% | 5.17% | 1.51% | 5.08% | 6.14% | 4.43% |
| Price to Book | 30.1 x | 7.3 x | 3.52 x | 1.94 x | 1.94 x | 1.79 x |
| Nbr of stocks (in thousands) | 1,000,000 | 1,000,111 | 1,000,770 | 961,936 | - | - |
| Reference price 2 | 4.532 | 2.388 | 1.423 | 0.7925 | 0.7925 | 0.7925 |
| Announcement Date | 6/17/21 | 6/1/22 | 6/1/23 | - | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 672.2 | 773 | 908.3 | 1,000 | 888 | 847.2 | 901.2 |
| EBITDA 1 | - | 224.2 | 263 | 245 | 195.2 | 144.3 | 185.6 |
| EBIT 1 | - | 193 | 229.3 | 176.2 | 123.9 | 68.87 | 103.6 |
| Operating Margin | - | 24.97% | 25.24% | 17.61% | 13.96% | 8.13% | 11.5% |
| Earnings before Tax (EBT) 1 | - | 70.9 | 214.3 | 159.4 | 91.86 | 39.86 | 65.91 |
| Net income 1 | 74.8 | 35.7 | 181.2 | 128.9 | 67.72 | 29.35 | 48.37 |
| Net margin | 11.13% | 4.62% | 19.95% | 12.89% | 7.63% | 3.46% | 5.37% |
| EPS 2 | - | 0.0360 | 0.1810 | 0.1290 | 0.0708 | 0.0311 | 0.0535 |
| Free Cash Flow 1 | - | 169.8 | 132.1 | 25.9 | 56.47 | 68.4 | 49 |
| FCF margin | - | 21.97% | 14.54% | 2.59% | 6.36% | 8.07% | 5.44% |
| FCF Conversion (EBITDA) | - | 75.74% | 50.23% | 10.57% | 28.93% | 47.39% | 26.39% |
| FCF Conversion (Net income) | - | 475.63% | 72.9% | 20.09% | 83.38% | 233.04% | 101.3% |
| Dividend per Share 2 | - | - | 0.0550 | 0.0584 | 0.0583 | 0.0327 | 0.0366 |
| Announcement Date | 10/2/20 | 6/17/21 | 6/1/22 | 6/1/23 | - | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 Q4 | 2024 S2 | 2025 Q3 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 454.8 | 369.9 | 538.4 | 418.6 | 581.7 | 395.8 | 213 | 486.9 | - |
| EBITDA | - | 88.8 | - | 88.8 | - | 77.6 | - | 116 | - |
| EBIT | - | - | - | - | - | 40.3 | - | - | 1.6 |
| Operating Margin | - | - | - | - | - | 10.18% | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | 25.8 | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | 0.0190 | - | - | - |
| Dividend per Share | - | - | - | - | - | 0.0156 | - | - | - |
| Announcement Date | 6/17/21 | 12/9/21 | 6/1/22 | 11/24/22 | 6/1/23 | 11/30/23 | - | - | - |
1GBP in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 174 | 166 | 288 | 349 | 351 | 345 |
| Net Cash position 1 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 0.7756 x | 0.6304 x | 1.177 x | 1.79 x | 2.433 x | 1.857 x |
| Free Cash Flow 1 | - | 170 | 132 | 25.9 | 56.5 | 68.4 | 49 |
| ROE (net income / shareholders' equity) | - | 105% | 75.8% | 35.2% | 17.2% | 7.39% | 14.7% |
| ROA (Net income/ Total Assets) | - | - | - | - | 6.49% | 3.01% | 4.25% |
| Assets 1 | - | - | - | - | 1,044 | 975.5 | 1,138 |
| Book Value Per Share 2 | - | 0.1500 | 0.3300 | 0.4000 | 0.4100 | 0.4100 | 0.4400 |
| Cash Flow per Share 2 | - | 0.1600 | 0.1800 | 0.0800 | 0.1300 | 0.1500 | 0.1600 |
| Capex 1 | - | 18.6 | 25 | 51.4 | 51 | 52 | 53.3 |
| Capex / Sales | - | 2.41% | 2.75% | 5.14% | 5.75% | 6.14% | 5.92% |
| Announcement Date | 10/2/20 | 6/17/21 | 6/1/22 | 6/1/23 | - | - | - |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
0.7925
GBP
Average target price
0.7677
GBP
Spread / Average Target
-3.13%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.55% | 954M | |
| +28.96% | 22.13B | |
| +29.33% | 11B | |
| +8.73% | 10.34B | |
| +53.38% | 8.7B | |
| -6.65% | 8.54B | |
| +20.39% | 3.38B | |
| +74.31% | 3.11B | |
| -5.74% | 2.54B | |
| -20.82% | 2.01B |
- Stock Market
- Equities
- DOCS Stock
- Financials Dr. Martens plc